ERCC1 expression in non-small cell lung and esophageal cancer
Yıl: 2014 Cilt: 46 Sayı: 2 Sayfa Aralığı: 84 - 88 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
ERCC1 expression in non-small cell lung and esophageal cancer
Öz: Amaç: “Excision Repair Cross-Complementation Group 1”(ERCC1) enzimi DNA tamiri için gerekli temel proteinlerden bir tanesi olup hayati öneme sahiptir. Yapılan son çalışmalarda ERCC1’in antrasiklin bazlı kemoterapi rejimlerine karşı gelişen direnç ile ilişkili olabileceğini düşündürmektedir. Bu çalışmada, ERCC1 ekspresyonunu küçük hücre dışı akciğer kanseri ve özofagus kanseri hastalarında araştırmayı amaçladık. Aynı zamanda ERCC1 ekspresyonu ile hastaların demografik verileriarasında olabilecek muhtemel ilişkiyi araştırmayı amaçladık. Gereç ve Yöntem: Aralık 2009 ve Aralık 2010 tarihleri arasında, endoskopik, bronkoskopik veya tru-cut biyopsi ile özofagus kanseri tanısı almış 20 hasta ve küçük hücre dışı akciğer kanseri (KHDAK) tanısı almış 20 hasta çalışmaya dahil edildi. Hastalara ait demografik bilgiler kayıt edildi. Çalışma sonunda ERCC1 ekspresyonu, tanı koydurucu patoloji bloklarından elde edilen dokusal RNA örneklerinde RT-PCR (reverse transcriptase-polymerase chain reaction) metodu ile değerlendirildi. Bulgular: Hastaların ERCC1 ekspresyon düzeyi ile TNM evrelemesi, Dünya sağlık örgütü (WHO) derecesi, yaş, cinsiyet, hemoglobulin ve albumin serum düzeyi gibi parameterelerin herhangi birisi ile korrelasyonu tespit edilemedi. KHDAK hastalarında ve özofagus kanseri hastalarında ölçülen ortalama ERCC1 ekspresyonu düzeyi sırası ile 0,71±0,85 and 0,62±0,78 olarak tespit edildi. ERCC1 expresyonu her iki hasta grubunun da %15’inde artmış olarak tespit edildi. Sonuç: ERCC1 ekspresyonun KHDAK ve özofagus kanseri hastalarında kemoterapi öncesi incelenmesi daha bireyselleştirilmiş kemoterapi rejimlerinin kullanılmasının yanında hasta ile ilgili daha doğru prognostik bilgi edinilmesini de sağlayacaktır..
Anahtar Kelime: Konular:
Küçük hücre dışı akciğer kanseri ve özofagus kanserinde ERCC1 ekspresyonu
Öz: Objective: “Excision Repair Cross-Complementation Group 1”(ERCC1) enzyme is a vitally important basic protein required for DNArepair. Recent studies suggest that ERCC1 is involved in resistance toantracycline-based chemotherapy regimens. In this study, we aimedto analyze ERCC1 expression in lung and esophageal cancer patients.We also aimed to investigate the possible correlation between theERCC1 expression levels and patient demographic information.Materials and Methods: Twenty esophageal and 20 non-small cell lung cancer (NSCLC) patients diagnosed between December 2009 and December 2010, via either endoscopic, bronchoscopic or tru-cut biopsy, were included in this study. The ERCC1 expression levels were analyzed by the reverse transcriptase-polymerase chain reaction (RT- PCR) method in RNA samples extracted from pathological biopsy specimens. The patient demographic information was also recorded. Results: There was no significant correlation between the ERCC1 expression level and demographic parameters, including the tumor, node, metastatis (TNM) staging, World Health Organization (WHO) grading, age, gender, hemoglobin level and albumin level, in the patient groups. The mean ERCC1 expression levels in the NSCLC and esophageal cancer patients were 0.71±0.85 and 0.62±0.78, respectively. The ERCC1 expression level was elevated in 15% of each patient group. Conclusion: Analysis of the ERCC1 expression in NSCLC and esophageal cancer patients prior to chemotherapy would be useful for personalized chemotherapy regimens and would provide more accurateprognostic information for the patient.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Warnecke-Eberz U, Vallböhmer D, Alakus H, et al. ERCC1 and XRCC1 Gene Polymorphisms Predict Response to Neoadjuvant Radiochemotherapy in Esophageal Cancer. J Gastrointest Surg 2009 13: 1411-21. [CrossRef]
- 2. Fareed KR, Al-Attar A, Soomro IN, et al. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemothera- py. British Journal of Cancer 2010; 102: 1600-7. [CrossRef]
- 3. Jennifer P, Jie L, Julie GI, et al. Genetic susceptibility to esopha- geal cancer: the role of the nucleotide excision repair pathway Carcinogenesis 2009; 30:785-92. [CrossRef]
- 4. Joshi MB, Shirota Y, Danenberg KD, Et al. High Gene Expression of TS1, GSTP1, and ERCC1 Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer. Clin Cancer Res 2005; 11: 2215-21. [CrossRef]
- 5. Wei J, Zou Z, Qian X, et al. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 2008; 98: 1398 -402. [CrossRef]
- 6. Allingham-Hawkins D, Lea A, Levine S. ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer PLoS Curr 2010; 6; 2: RRN1202
- 7. Olaussen KA, Mountzios G, Soria JC. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med. 2007; 13: 284-9. [CrossRef]
- 8. Mountzios G, Dimopoulos MA, Papadimitriou C. Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer. Biomark Insights 2008; 17: 219-26.
- 9. Osawa K. Gene Polymorphisms and Chemotherapy in Non- small Cell LungCancer. Chin J Lung Cancer 2009; 12: 837-40.
- 10. Taillade L, Penault-Llorca F, Boulet T, et al. Immunohistochemichal expression of biomarkers: a comparative study between diag- nostic bronchial biopsies and surgical specimens of non-small- cell lung cancer. Ann Oncol 2007; 18: 1043-50. [CrossRef]
- 11. Gomez-Roca C, Raynaud CM, Penault-Llorca F, et al. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol 2009 ; 4: 1212-20. [CrossRef]
- 12. George RS, Swati S, Alan C, Prudence S, Gerold B. ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer* Chest 2005; 127; 978-83.
| APA | Bilen N, TEKİN B, TOPDAGİ O (2014). ERCC1 expression in non-small cell lung and esophageal cancer. , 84 - 88. |
| Chicago | Bilen Nurhan,TEKİN B. Salim,TOPDAGİ Omer ERCC1 expression in non-small cell lung and esophageal cancer. (2014): 84 - 88. |
| MLA | Bilen Nurhan,TEKİN B. Salim,TOPDAGİ Omer ERCC1 expression in non-small cell lung and esophageal cancer. , 2014, ss.84 - 88. |
| AMA | Bilen N,TEKİN B,TOPDAGİ O ERCC1 expression in non-small cell lung and esophageal cancer. . 2014; 84 - 88. |
| Vancouver | Bilen N,TEKİN B,TOPDAGİ O ERCC1 expression in non-small cell lung and esophageal cancer. . 2014; 84 - 88. |
| IEEE | Bilen N,TEKİN B,TOPDAGİ O "ERCC1 expression in non-small cell lung and esophageal cancer." , ss.84 - 88, 2014. |
| ISNAD | Bilen, Nurhan vd. "ERCC1 expression in non-small cell lung and esophageal cancer". (2014), 84-88. |
| APA | Bilen N, TEKİN B, TOPDAGİ O (2014). ERCC1 expression in non-small cell lung and esophageal cancer. Eurasian Journal of Medicine, 46(2), 84 - 88. |
| Chicago | Bilen Nurhan,TEKİN B. Salim,TOPDAGİ Omer ERCC1 expression in non-small cell lung and esophageal cancer. Eurasian Journal of Medicine 46, no.2 (2014): 84 - 88. |
| MLA | Bilen Nurhan,TEKİN B. Salim,TOPDAGİ Omer ERCC1 expression in non-small cell lung and esophageal cancer. Eurasian Journal of Medicine, vol.46, no.2, 2014, ss.84 - 88. |
| AMA | Bilen N,TEKİN B,TOPDAGİ O ERCC1 expression in non-small cell lung and esophageal cancer. Eurasian Journal of Medicine. 2014; 46(2): 84 - 88. |
| Vancouver | Bilen N,TEKİN B,TOPDAGİ O ERCC1 expression in non-small cell lung and esophageal cancer. Eurasian Journal of Medicine. 2014; 46(2): 84 - 88. |
| IEEE | Bilen N,TEKİN B,TOPDAGİ O "ERCC1 expression in non-small cell lung and esophageal cancer." Eurasian Journal of Medicine, 46, ss.84 - 88, 2014. |
| ISNAD | Bilen, Nurhan vd. "ERCC1 expression in non-small cell lung and esophageal cancer". Eurasian Journal of Medicine 46/2 (2014), 84-88. |
